Clinical Trial

Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer

Study acronym: REDEEM-CAD
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 4, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 years ago.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-05-04; most recent amendment 2025-11-27.
Status change: Not Yet Recruiting → Recruiting 2024-08-20
Trial Details
NCT Number NCT05366153
Lead Sponsor Baker Heart and Diabetes Institute
Collaborators: Western Health, Australia, Northern Hospital, Australia, Menzies Institute for Medical Research, Peter MacCallum Cancer Centre, Australia, The Alfred
Conditions Coronary Artery Disease
Enrollment 748 participants
Start Date 2023-10-18
Primary Completion 2026-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2025-12-04